EB-373

EB-373 is a proprietary next-generation small-molecule prodrug of psilocin developed by Enveric Biosciences. It is designed as a novel neuroplastogenic therapeutic for the treatment of anxiety disorders and other mental health conditions such as depression and addiction. Developed using Enveric’s Psybrary drug discovery platform, EB-373 incorporates metabolically amenable functional groups to alter absorption and pharmacokinetics compared to traditional psilocybin or psilocin. Preclinical studies have demonstrated that orally administered EB-373 rapidly converts to active psilocin in vivo, resulting in dose-dependent induction of characteristic serotonergic responses (e.g., head twitch response in mice) and robust anxiolytic effects in animal models such as the Marble Burying Test. The compound aims to provide rapid onset with controlled duration of psychedelic experience while maintaining long-term mental health benefits[1][4][5][6][9].

Other names

psilocin prodrug (Enveric Biosciences)